葛兰素史克Glaxosmithkline（GSK）2025年第一季度投资者和分析师财报电话会议PPT「LSE」（英文版）（41页）.pdf

1、Q1 2025 ResultsConference call and webcast for investors and analystsConference call and webcast for investors and analysts30 April 202530 April 20252AgendaAgendaQ1 2025 performance on trackQ1 2025 performance on trackEmma WalmsleyPerformance:growth driversPerformance:growth driversLuke Miels and Da

2、vid RedfernQ1 2025 financial performanceQ1 2025 financial performanceJulie BrownSummary and Q&ASummary and Q&AEmma Walmsley,Luke Miels,David Redfern,Julie Brown and Tony Wood3This presentation may contain forward-looking statements.Forward-looking statements give the Groups current expectations or f

3、orecasts of future events.An investor can identify these statements by the fact that they do not relate strictly to historical or current facts.They use words such as anticipate,estimate,expect,intend,will,project,plan,believe,target and other words and terms of similar meaning in connection with an

4、y discussion of future operating or financial performance.In particular,these include statements relating to future actions,prospective products or product approvals,future performance or results of current and anticipated products,sales efforts,expenses,the outcome of contingencies such as legal pr

5、oceedings,dividend payments and financial results.Other than in accordance with its legal or regulatory obligations(including under the Market Abuse Regulations,UK Listing Rules and the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority),the Group undertakes no obligation

6、to update any forward-looking statements,whether as a result of new information,future events or otherwise.Investors should,however,consult any additional disclosures that the Group may make in any documents which it publishes and/or files with the US Securities and Exchange Commission(SEC).All inve